<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A case of carbamazepine-induced <z:hpo ids='HP_0001882'>leukopenia</z:hpo> with subsequent successful carbamazepine management is presented </plain></SENT>
<SENT sid="1" pm="."><plain>Despite WBC suppression to a level of 2000/cu mm on an initial trial of carbamazepine, a challenge with a much lower dose and gradual titration permitted a full treatment course with therapeutic blood levels </plain></SENT>
<SENT sid="2" pm="."><plain>Although many physicians are wary of the <z:hpo ids='HP_0001882'>leukopenia</z:hpo> associated with carbamazepine, it is a distinct entity from the rare <z:mp ids='MP_0000334'>agranulocytosis</z:mp> and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> that have been associated with the drug </plain></SENT>
<SENT sid="3" pm="."><plain>With careful clinical management, carbamazepine can be successfully used in patients with <z:e sem="disease" ids="C0027765" disease_type="Disease or Syndrome" abbrv="">neurologic disorders</z:e> despite significant WBC suppression </plain></SENT>
</text></document>